ESSA Pharma Inc. (EPIX) Sees Large Volume Increase
Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) saw unusually-strong trading volume on Friday . Approximately 938,247 shares traded hands during trading, an increase of 512% from the previous session’s volume of 153,272 shares.The stock last traded at $0.50 and had previously closed at $0.44.
A number of analysts have commented on EPIX shares. ValuEngine lowered shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 7th. Zacks Investment Research upgraded shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Dawson James restated a “buy” rating on shares of ESSA Pharma in a research note on Thursday, August 3rd. Finally, Bloom Burton restated a “buy” rating on shares of ESSA Pharma in a research note on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $9.00.
The stock has a 50 day moving average of $0.35 and a 200-day moving average of $1.44. The stock’s market capitalization is $14.23 million.
WARNING: “ESSA Pharma Inc. (EPIX) Sees Large Volume Increase” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/08/essa-pharma-inc-epix-sees-large-volume-increase.html.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.